Anti-aging drug combination shows promise for treating back pain – mahrgan

Philadelphia- This is good news for the millions of people who struggle with back pain every day. Scientists have developed an injection that can kill back pain in the bud.It contains a mixture of anti-aging drugs called senolytics Kill the “zombie cell”.

Chronic back pain affects more than 15 million adults in the United States, causing billions of dollars in health care costs and lost workdays. Injections can protect people from this serious disease for decades. Clinical trials are already planned.

In the experiment, young and middle-aged mice grew up with less disc degeneration compared with their peers who took a placebo. They also have fewer senescent cells that stop dividing and release chemicals that cause inflammation. They are called zombie cells because they are damaged but refuse to die.

“Once the intervertebral disc begins to degenerate, almost no regeneration occurs. But our results show that it is possible to reduce the degeneration of the intervertebral disc that occurs with aging.” Liesbard said in a statement.

The spine “cushion” that supports the vertebrae will dry out over the years and cannot absorb shocks. Simple daily activities and sports can cause tearing of the outer core. Most people over 60 have some deterioration. There are few treatments available. Most patients do not meet the criteria for surgery or steroid injections, which are usually ineffective. Long-term use of strong painkillers, such as opioids, is at risk of addiction.

Now Jefferson’s team has proposed a new method of combining drugs Dasatinib with Quercetin, A drug that removes senescent cells. Over time, every tissue in the body collects them. They secrete destructive enzymes and proteins that destroy healthy cells.

Senolytics leaves room for fresh formation. Researchers say this non-invasive technique paves the way for the treatment of back pain. These two drugs are currently being tested in humans to treat lung scars. They have also been shown to be able to deal with the intervertebral discs in the spine, but in a surprising way. “Just because drugs work in one tissue does not mean they will also work in another tissue. Every type of tissue is different,” Dr. Risbud said.

Weekly injections reduce the formation of intervertebral discs, which works best in middle-aged and young laboratory rodents, not their elders. They actually have a protective effect. It is believed that the oldest animals will benefit the most because they have more senescent cells.

“we estimate [that] In a large number of senescent tissues, removing senescent cells makes a big difference, but this is not the case. This therapy is most effective when we start treating mice when these senescent cells have just begun to appear. Our research results show that if given early, aging drugs can actually slow the degeneration of the intervertebral disc. This is a novel prevention method,” Dr. Risbud explained.

These animals need to be injected once a week until they get old-which is much longer than the aging drugs used before. However, no side effects were found during the long-term treatment. “People may need to take it for a long time for the treatment to be effective. Our data shows that these drugs are well tolerated-at least in mice,” Dr. Reesbard said.

Research Shows that senolytics, which has been approved for clinical trials, can combat age-related disc degeneration. “This research paves the way for these studies to be first transformed into preclinical animal models and then into human clinical trials,” Dr. Risbud added.

Senolytics is hailed as a new weapon against aging, and it is possible to treat a series of diseases that plague the elderly. Some scientists believe that they hold the key to immortality. The ultimate dream is a panacea: a panacea to cure the disease of aging.

The research was published in Nature Communications.

Southwest News Agency writer Mark Waghorn contributed to this report.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *